Overview
This combination unites two compounds that reach growth hormone release from opposite sides of the axis: CJC-1295 (No DAC), a short-acting GHRH analog acting upstream through the GHRH receptor, and Ipamorelin, a highly selective pentapeptide agonist of GHS-R1a. Each pathway converges on somatotroph GH granule release through different intracellular routes, which is the scientific rationale for studying them together in a single pre-formulated blend.
Mechanism of Action
In somatotroph preparations, CJC-1295 (No DAC) activates Gs-coupled cAMP/PKA signaling while Ipamorelin engages Gq/11-mediated phospholipase C, IP3-dependent calcium release, and PKC activation. Applied together, the two cascades produce GH release responses consistent with pharmacological synergy — exceeding the output of either compound alone at equivalent concentrations. Ipamorelin's minimal off-target activity at adrenocortical and lactotroph receptor systems keeps the experimental background clean.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder, pre-blended
- Composition: CJC-1295 (No DAC) + Ipamorelin
- CAS Numbers: CJC-1295: 446036-97-1 · Ipamorelin: 170851-70-4
- Molecular Weights: CJC-1295: ~3367.9 g/mol · Ipamorelin: 711.86 g/mol
Research Applications
- GH-axis synergy and dual-secretagogue protocols
- GHRHR vs GHS-R1a pathway convergence studies
- GHS-R1a selectivity profiling
- Pulsatile GH secretion modeling
- Secretagogue comparative pharmacology





